Ann Arbor-based Velcura Therapeutics Inc. today was to announce the appointment of three new experts to the company's scientific advisory board. They are Julie Glowacki, Ph.D., professor in the department of orthopedic surgery and professor in the department of oral-maxillofacial surgery at the Harvard University school of medicine; John Lowe, M.D., professor in the department of pathology and Warner Lambert/Parke-Davis professor in the department of medicine at the University of Michigan; and W. Stratford May, M.D., Ph.D., director of the Shands Cancer Center and Harry F. Innes professor of cancer research at the University of Florida. The company is developing new and better ways to treat osteoporosis and other bone disorders. Glowacki's research examines the function of engineered joints, the molecular mechanism by which damaged bone initiates cartilage formation, and mechanisms by which steroid therapies increase bone mass. Lowe's work centers on the molecular control of protein modification events in inflammation and disease. May's research centers on protein signaling in cancer and other diseases.